Breakthrough Hope: A Revolutionary Advance in Treating Brain Cancer Called Glioma - SurvivorNet
Vorasidenib, a dual inhibitor of IDH1 and IDH2 mutations, offers a breakthrough in treating IDH-mutated, grade two glioma, significantly improving progression-free survival and crossing the blood-brain barrier effectively.
Related Clinical Trials
Reference News
Vorasidenib, a dual inhibitor of IDH1 and IDH2 mutations, offers a breakthrough in treating IDH-mutated, grade two glioma, significantly improving progression-free survival and crossing the blood-brain barrier effectively.
Biologics by McKesson selected by Servier as a limited specialty pharmacy provider for VORANIGO (vorasidenib), a targeted drug for Grade 2 IDH-mutant gliomas, approved by the FDA on August 6, 2024.
Voranigo (vorasidenib), an IDH1/IDH2 inhibitor by Servier Pharmaceuticals, was approved by the FDA in August for treating grade 2 astrocytoma or oligodendroglioma with IDH1 or IDH2 mutations. A phase 3 trial showed Voranigo doubled progression-free survival to 27.7 months compared to 11.1 months with a placebo.
Vorasidenib (Voranigo) received FDA approval for IDH1/2-mutant glioma treatment, marking the first systemic medication for low-grade glioma in over 20 years. The INDIGO trial showed a median progression-free survival of 27.7 months with vorasidenib vs 11.1 months with placebo. Vorasidenib is well-tolerated, with common side effects being fatigue, headache, and nausea, mostly grade 1. The approval allows for broader use, but careful patient-provider discussions are essential due to potential overtreatment risks and patient-specific considerations.